Editors: Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar, and Barbara J. EvansPublisher: Cambridge University PressPublication Date: June 2019 This edited volume stems from the Petrie-Flom Center’s 2017 annual conference, which brought together leading experts to reach better understandings of this health policy buzzword, recognizing its true limitations, so that transparency can be utilized as a solution…
In my forthcoming article, I argue that our cancer regulatory regimes inadequately protect the public.
What does it mean when our devices recognize us more accurately when we utter the dialect of consumerism?
Initiatives like CalRx may have far-reaching consequences for public health and access to medicines.
The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.
While issues of influence affecting Supreme Court Justices attract the most attention, the factors that make Justices targets extend across the entire federal judiciary.
The regulatory landscape of health-related products contains loopholes that allow false or misleading claims to proliferate.
FOIA backlogs have increased during COVID-19 and now exceed 140,000. Fortunately, much could be done to strengthen FOIA in the coming year.
Advertisers are trying to market to us while we dream — a troubling and potentially illegal new reality.
Massive and misleading promises are an unfortunate reality for many fitness products. But regulators can promote accountability.
